Mo-MDSCs are pivotal players in colorectal cancer and may be associated with tumor recurrence after surgery

Siemińska, Izabela; Węglarczyk, Kazimierz; Walczak, Marta; Czerwińska, A; Pach, Radosław; Rubinkiewicz, Mateusz; Szczepanik, Antoni M.; Siedlar, Maciej; Baran, Jarek

doi:10.1016/j.tranon.2022.101346

Cited by 10 publications

(7 citation statements)

References 40 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with solid tumors, the number of MDSCs is positively correlated with cancer stage and tumor load [ 11 , 12 ] and is a biological marker of treatment failure as well as poor prognosis [ 13 – 15 ]. Under the joint regulation of the tumor microenvironment and tumor-derived factors secreted by cancer cells, MDSCs can be amplified and recruited to tumor primary and metastatic sites [ 16 , 17 ], while activated MDSCs can suppress the anti-tumor immune response of immune cells (e.g., NK cells, CD4 + T cells, and CD8 + T cells) through numerous mechanisms (e.g., the release of nitric oxide or reactive oxygen species [ 7 ], depletion of essential metabolites [ 8 ], induction of other immunosuppressive cells [ 9 ], and expression of negative immune checkpoint molecules [ 10 ]) in the tumor microenvironment, thus promoting tumor cells immune tolerance and leading to their immune escape.…”

Section: Introductionmentioning

confidence: 99%

Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin

Ren

2022

Exp Hematol Oncol

View full text Add to dashboard Cite

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of bone marrow cells originating from immature myeloid cells. They exert potent immunosuppressive activity and are closely associated with the development of various diseases such as malignancies, infections, and inflammation. In malignant tumors, MDSCs, one of the most dominant cellular components comprising the tumor microenvironment, play a crucial role in tumor growth, drug resistance, recurrence, and immune escape. Although the role of MDSCs in solid tumors is currently being extensively studied, little is known about their role in hematologic malignancies. In this review, we comprehensively summarized and reviewed the different roles of MDSCs in hematologic malignancies and hematopoietic stem cell transplantation, and finally discussed current targeted therapeutic strategies.Affiliation: Kindly check and confirm the processed affiliations are correct. Amend if any.correct

show abstract

Section: Introductionmentioning

confidence: 99%

Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin

Ren

2022

Exp Hematol Oncol

View full text Add to dashboard Cite

show abstract

“…MDSCs perform an important role in tumorigenesis and progression of cancer by primarily inhibiting T cell proliferation and activation via direct interaction, metabolic depletion, and cytokine modulation [ 35 , 60 , 61 ]. For instance, M-MDSCs significantly promote the activation of dormant micro-metastatic cells compared to PMN-MDSCs [ 62 , 63 ]. In acute myeloid leukemia (AML), elevated M-MDSC count is significantly associated with poor prognosis [ 64 ].…”

Section: Monocytes and Monocyte-derived Cells In Tumorigenesismentioning

confidence: 99%

Monocytes in Tumorigenesis and Tumor Immunotherapy

Chen

Xia

et al. 2023

Cells

View full text Add to dashboard Cite

Monocytes are highly plastic innate immune cells that display significant heterogeneity during homeostasis, inflammation, and tumorigenesis. Tumor-induced systemic and local microenvironmental changes influence the phenotype, differentiation, and distribution of monocytes. Meanwhile, monocytes and their related cell subsets perform an important regulatory role in the development of many cancers by affecting tumor growth or metastasis. Thanks to recent advances in single-cell technologies, the nature of monocyte heterogeneity and subset-specific functions have become increasingly clear, making it possible to systematically analyze subset-specific roles of monocytes in tumorigenesis. In this review, we discuss recent discoveries related to monocytes and tumorigenesis, and new strategies for tumor biomarker identification and anti-tumor immunotherapy.

show abstract

“…In metastatic CRC, it was found that high numbers of G-MDSC were associated with poor prognosis [ 60 ]. Moreover, levels of circulating M-MDSCs were significantly elevated in most advanced tumor stages of CRC patients [ 66 ]. Additionally, levels of circulating M-MDSCs were significantly elevated after surgery, indicating that M-MDSCs levels are related to disease burden and tumor recurrence [ 66 ].…”

Section: Prognostic Significance Of Mdscs In Crcmentioning

confidence: 99%

“…Moreover, levels of circulating M-MDSCs were significantly elevated in most advanced tumor stages of CRC patients [ 66 ]. Additionally, levels of circulating M-MDSCs were significantly elevated after surgery, indicating that M-MDSCs levels are related to disease burden and tumor recurrence [ 66 ]. Similarly, expansion of circulating G-MDSCs was found to be correlated with higher stage and histological grade of malignancy, indicating their role in cancer progression [ 48 ].…”

Section: Prognostic Significance Of Mdscs In Crcmentioning

confidence: 99%

Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets

Al-Mterin

Elkord

2022

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Myeloid-derived suppressor cells (MDSCs) are a group of immature myeloid cells, which are expanded in most cancer patients. MDSCs suppress host immune responses, leading to cancer growth and progression. Several studies demonstrated that there was a relationship between levels of MDSCs and tumorigenesis in colorectal cancer (CRC) patients. MDSCs are now being investigated for their role as possible therapeutic targets in cancer treatment. This review summarizes available studies that investigated MDSC expansion in CRC patients, as well as their role in CRC tumorigenesis, prognosis, and targeting. Based on the available studies, there is a possible relationship between high levels of MDSCs and CRC progression. Additionally, targeting MDSCs in CRC patients selectively represents a significant challenge for the development of targeted treatments. Targeting of MDSCs could be exploited in different ways including MDSC depletion, inhibition of MDSC function and recruitment, and enhancing MDSC differentiation. Overall, MDSCs could be exploited as prognostic biomarkers and potential therapeutic targets in CRC.

show abstract

Mo-MDSCs are pivotal players in colorectal cancer and may be associated with tumor recurrence after surgery

Cited by 10 publications

References 40 publications

Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin

Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin

Monocytes in Tumorigenesis and Tumor Immunotherapy

Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets

Contact Info

Product

Resources

About